SCHEMBL3245447

SCHEMBL3245447

CC(=O)S(=O)(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
HTT P42858 2/20 0.53
BCAT1 P54687 1/20 0.50
TSHR P16473 1/20 0.50
KMT2A Q03164 1/20 0.48
HTR6 P50406 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 1/20 0.47
PSIP1 O75475 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HSD11B1 P28845 3/20 0.45
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
MMP13 P45452 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469289 0.82 SMN1; SMN2 (0.52) SMN1; SMN2HTTBCAT1TSHRKMT2A
SCHEMBL15062217 0.82 SMN1; SMN2 (0.52) SMN1; SMN2HTTBCAT1TSHRKMT2A
SCHEMBL9711936 0.79 CA2 (0.57) SMN1; SMN2TSHRKMT2AALDH1A1HSD17B10
SCHEMBL3828442 0.79 SMN1; SMN2 (0.55) SMN1; SMN2HTTBCAT1TSHRHTR6
SCHEMBL7266697 0.79 SMN1; SMN2 (0.55) SMN1; SMN2HTTBCAT1TSHRKMT2A
SCHEMBL9043625 0.78 SMN1; SMN2 (0.48) SMN1; SMN2HTTBCAT1TSHRKMT2A
SCHEMBL9732594 0.78 SMN1; SMN2 (0.48) SMN1; SMN2HTTBCAT1TSHRKMT2A
SCHEMBL11107252 0.78 GAA (0.54) SMN1; SMN2HTTKMT2AALDH1A1LMNA
SCHEMBL12588794 0.78 SMN1; SMN2 (0.47) SMN1; SMN2HTTBCAT1TSHRKMT2A
(Phenylsulfonyl)Benzene SCHEMBL2381369 0.77 HTR6 (0.74) SMN1; SMN2BCAT1TSHRKMT2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4127580-A MULTISTAGE PARCOR (FR) 1978-11-28 US claimed
CN-118598780-A Aggregation-induced emission naphthyl benzenesulfonyl ethanone and preparation thereof 内蒙古工业大学 2024-09-06 CN disclosed
CN-110036022-A Antibody-coupled cyclic peptide tyrosine compounds as modulators of neuropeptide Y receptors 詹森药业有限公司 2019-07-19 CN disclosed
CN-103841991-B Diagnosis and the method for the treatment of blood vessel related maculopathy and its symptom 犹他大学研究基金会 2018-03-27 CN disclosed
CN-106687128-A Compositions and methods for treating metabolic disorders NGM生物制药有限公司 2017-05-17 CN disclosed
CN-102361857-A Novel cyclic benzimidazole derivatives useful anti-diabetic agents MERCK SHARP & DOHME 2012-02-22 CN disclosed
CN-102271511-A Novel cyclic benzimidazole derivatives useful anti-diabetic agents 2011-12-07 CN disclosed
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
US-7199139-B2 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
EP-1354602-B1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT SANKYO CO (JP) 2006-10-04 EP disclosed
EP-1354602-A1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT Sankyo Company, Limited (JP) 2003-10-22 EP disclosed
US-6596751-B2 An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose SANKYO COMPANY LIMITED (JP) 2003-07-22 US disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-20030069294-A1 Alpha-substituted carboxylic acid derivatives SANKYO COMPANY, LIMITED (JP) 2003-04-10 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
EP-1167357-A1 ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
US-5026740-A For transparent or pigmented mixtures FRATELLI LAMBERTI S.P.A. (IT) 1991-06-25 US disclosed
EP-0192967-B1 SULPHURATED DERIVATIVES OF AROMATIC-ALIPHATIC AND ALIPHATIC KETONES AS POLYMERISATION PHOTOINITIATORS FRATELLI LAMBERTI S.p.A. (IT) 1990-08-01 EP disclosed
EP-0192967-A1 Sulphurated derivatives of aromatic-aliphatic and aliphatic ketones as polymerisation photoinitiators FRATELLI LAMBERTI S.p.A. (IT) 1986-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069294-A1 Alpha-substituted carboxylic acid derivatives SLC5A1, SLC2A1, GPR119 SMN1; SMN2 2259/4885HTT 4507/4885BCAT1 20/4885
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 SMN1; SMN2 3933/4885HTT 3024/4885BCAT1 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.